{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:42:27Z","timestamp":1764700947412,"version":"3.37.3"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"8","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute on Neurologic Disorders and Stroke","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003645","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.1093\/neuonc\/noac081","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T20:11:48Z","timestamp":1647979908000},"page":"1387-1388","source":"Crossref","is-referenced-by-count":2,"title":["Identifying risk factors for recurrence\/relapse in NF1 optic pathway gliomas: Moving forward by looking back"],"prefix":"10.1093","volume":"24","author":[{"given":"Anna F","family":"Piotrowski","sequence":"first","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6700-5621","authenticated-orcid":false,"given":"Sadhana","family":"Jackson","sequence":"additional","affiliation":[{"name":"Surgical Neurology Branch, NINDS, and Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"2023052519071740700_CIT0001","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/neuonc\/nos076","article-title":"Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis","volume":"14","author":"Fisher","year":"2012","journal-title":"Neuro Oncol."},{"key":"2023052519071740700_CIT0002","first-page":"4095","article-title":"Optic pathway glioma and cerebral focal abnormal signal intensity in patients with neurofibromatosis type 1: characteristics, treatment choices and follow-up in 134 affected individuals and a brief review of the literature","volume":"36","author":"Friedrich","year":"2016","journal-title":"Anticancer Res."},{"key":"2023052519071740700_CIT0003","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/pbc.22198","article-title":"Natural history and outcome of optic pathway gliomas in children","volume":"53","author":"Nicolin","year":"2009","journal-title":"Pediatr Blood Cancer."},{"key":"2023052519071740700_CIT0004","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/neuonc\/noaa153","article-title":"NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat","volume":"23","author":"Azizi","year":"2021","journal-title":"Neuro Oncol."},{"journal-title":"Neuro Oncol.","article-title":"Risk factors for treatment refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1","author":"Kotch","key":"2023052519071740700_CIT0005"},{"key":"2023052519071740700_CIT0006","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(20)30064-4","article-title":"Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group","volume":"21","author":"Fangusaro","year":"2020","journal-title":"Lancet Oncol."},{"key":"2023052519071740700_CIT0007","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/jmg.2010.081760","article-title":"A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations","volume":"48","author":"Sharif","year":"2011","journal-title":"J Med Genet."},{"key":"2023052519071740700_CIT0008","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1212\/01.wnl.0000435745.95155.b8","article-title":"Functional outcome measures for NF1-associated optic pathway glioma clinical trials","volume":"81","author":"Fisher","year":"2013","journal-title":"Neurology."},{"key":"2023052519071740700_CIT0009","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.1993.11.5.850","article-title":"Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood","volume":"11","author":"Packer","year":"1993","journal-title":"J Clin Oncol."},{"key":"2023052519071740700_CIT0010","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for chemotherapy-na\u00efve children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium Study","volume":"34","author":"Lassaletta","year":"2016","journal-title":"J Clin Oncol."},{"key":"2023052519071740700_CIT0011","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00401-021-02276-5","article-title":"Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1)","volume":"141","author":"Fisher","year":"2021","journal-title":"Acta Neuropathol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noac081\/43386240\/noac081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/8\/1387\/50453787\/noac081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/8\/1387\/50453787\/noac081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T19:43:16Z","timestamp":1685043796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/24\/8\/1387\/6553267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":11,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,3,23]]},"published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noac081","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"type":"print","value":"1522-8517"},{"type":"electronic","value":"1523-5866"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,3,23]]}}}